Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin added to insulin in Japanese T2DM
NCT00854035Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin + Insulin with Placebo + Insulin (2 arms). Primary endpoints: Hemoglobin A1c at 16 weeks and Safety and Tolerability at 52 weeks. Started Feb 2009; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00854035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854035.